Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies

Gynecologic Oncology

Volumn 138, Issue 1, 2015, Pages 201-206

  Horowitz, Neil S ^a,b   Wright, Alexi A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Dosing; Endometrial cancer; Obesity; Ovarian cancer; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

BODY MASS; BODY SURFACE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; DOSE CALCULATION; ENDOMETRIUM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; GLOMERULUS FILTRATION RATE; HUMAN; OBESITY; OVARY CANCER; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; UNDERWEIGHT; COMPLICATION; GENITAL NEOPLASMS, FEMALE; METABOLISM;

ANTINEOPLASTIC AGENTS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; OBESITY;

EID: 84931572118     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.04.002     Document Type: Review

References (66)

1. T. Kelly, W. Yang, and C.S. Chen Global burden of obesity in 2005 and projections to 2030 Int. J. Obes. 32 2008 1431 1437
2. World Health Organization Obesity and overweight http://www.who.int/mediacentre/factsheets/fs311/en(2013) 2013
3. C.L. Ogden, M.D. Carroll, and K.M. Flegal Prevalence of childhood and adult obesity in the United States, 2011-2012 JAMA 311 8 2014 806 814
4. C. Eheman, S.J. Henley, R. Ballard-Barbash, E.J. Jacobs, M.J. Schymura, A.M. Noone, L. Pan, R.N. Anderson, J.E. Futon, B.A. Kohler, Ward E. JemalA, M. Plescia, L.A. Ries, and B.K. Edwards Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity Cancer 118 2012 2338 2366
5. D.W. Haslam, and W.P. James Obesity Lancet 366 2005 1197 1209
6. G.K. Reeves Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study BMJ 335 2007 1134
7. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, and M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults NEJM 348 17 2003 1625 1638
8. W. Demark-Wahnefried, E.A. Platz, J.A. Ligibel, C.K. Blair, K.S. Coumeya, J.A. Meyerhardt, P.A. Ganz, C.L. Rock, K.H. Schmitz, T. Wadden, E.J. Phillip, B. Wolfe, S.M. Gapstur, R. Ballard-Barbash, A. McTiernan, L. Minasian, L. Nebeling, and P.J. Goodwin The role of obesity in cancer survival and recurrence Cancer Epidemiol. Biomarkers Prev. 21 8 2012 1244 1259
9. D. Pinkel The use of body surface area as a criterion of drug dosage in cancer chemotherapy Cancer Res. 18 1958 853 856
10. M.P. Pai Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults Pharmacotherapy 32 9 2012 856 868
11. J.J. Griggs, P.B. Mnagu, H. Anderson, E.P. Balaban, J.J. Dignam, W.M. Hryniuk, V.A. Morrison, T.M. Pini, C.D. Runowicz, G.L. Rosner, M. Shayne, A. Sparreboom, L.E. Sucheston, and G.H. Lyman Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guidelines J. Clin. Oncol. 30 2012 1553 1561
12. C.H. Smorenburg, A. Sparreboom, M. Bontenbal, G. Stoter, K. Nooter, and J. Verweij Randomized cross-over evaluation of body-surface area based doing versus flat fixed dosing of paclitaxel J. Clin. Oncol. 21 2003 197 202
13. E. Chatelut Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents Br. J. Cancer 107 2012 1100 1106
14. D.W. Cockroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
15. J.G. Wright, A.V. Boddy, and M. Highley Estimation of glomerular filtration rate in cancer patients Br. J. Cancer 84 2001 452 459
16. R.W. Jelliffe Creatinine clearance: bedside estimate Ann. Intern. Med. 79 1973 604 605
17. S. Nagao, K. Fujiwara, N. Imafuku, R. Kagawa, Y. Kozuka, T. Oda, K. Maehata, H. Ishikawa, H. Koike, E. Aotani, and Kohno Ichiro Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright, or Chatelut formula Gynecol. Oncol. 99 2005 327 333
18. A. Schmitt, L. Gladieff, A. Lansiaux, C. Bobin-Dubigeon, M.C. Etienne-Grimaldi, and M. Boisdron-Celle A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients Clin. Cancer Res. 15 10 2009 3633 3639
19. R.A. Blouin, and G.W. Warren Pharmacokinetic considerations in obesity J. Pharm. Sci. 88 1999 1 7
20. P.A. Jansson, A. Larsson, and P.N. Lonnroth Relationship between blood pressure, metabolic variables, and blood flow in obese subjects with and without noninsulin-dependent diabetes mellitus Eur. J. Clin. Investig. 28 1998 813 818
21. E.D. Abel, S.E. Litwin, and G. Sweeney Cardiac modeling in obesity Physiol. Rev. 88 2008 389 419
22. M.J. Hanley, D.R. Abernathy, and D.J. Greenblatt Effect of obesity on the pharmacokinetics of drugs in humans Clin. Pharmacokinet. 49 2010 71 87
23. U.M. Hollenstein, A.M. Brunner, R. Schmid, and M. Muller Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight adjusted dosing Int. J. Obes. Relat. Metab. Disord. 25 2001 354 358
24. S. Ijaz, W. Yang, M.C. Winslet, and A.M. Seifalian Impairment of hepatic microcirculation in fatty liver Microcirculation 10 2003 447 456
25. P.Y. Han, S.B. Duffull, and C.M. Kirkpatrick Dosing in obesity: a simple solution to a big problem Clin. Pharmacol. Ther. 82 2007 505 508
26. A. Sparreboom, A.C. Wolff, R.H. Mathijssen, E. Chatelut, E.K. Rowinsky, J. Verweij, and S.D. Baker Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese J. Clin. Oncol. 25 2007 4707 4713
27. M. Gibaldi Revisiting some factors contributing to variability Ann. Pharmacother. 26 7-8 1992 1002 1007
28. N.H. Holford Target concentration intervention: beyond Y2K Br. J. Clin. Pharmacol. 52 2001 55S 59S (Suppl.)
29. W.E. Evans, and M.V. Relling Clinical pharmacokinetics-pharmacodynamics of anticancer drugs Clin. Pharmacokinet. 16 1989 327 336
30. A.E. Harvey, L.M. Lashinger, and S.D. Hursting The growing challenge of obesity and cancer: an inflammatory issue Ann. N. Y. Acad. Sci. 1229 2011 45 52
31. L.M. Lashinger, E.L. Rossi, and S.D. Hursting Obesity and resistance to cancer chemotherapy: interacting roles of inflammation and metabolic dysregulation Clin. Pharmacol. Ther. 96 4 2014 458 463
32. R.K. Hanna, M.S. Poniewierski, R.A. Laskey, M.A. Lopez, A. Shafer, L. Van Le, J. Craford, D.C. Dale, P.A. Gehrig, A.A. Secord, L.J. Havrilesky, and G.H. Lyman Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer Gynecol. Oncol. 129 2013 74 80
33. G.H. Lyman, and A. Sparreboom Chemotherapy dosing in overweight and obese patients with cancer Nat. Rev. Clin. Oncol. 10 2013 451 459
34. E. Frie III, and G.P. Canellos Dose: a critical factor in cancer chemotherapy Am. J. Med. 69 1980 585 594
35. F.M. Schabel Jr. The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors Cancer Res. 29 1969 2384 2389
36. J.H. Goldie, and A.J. Coldman The genetic origin of drug resistance in neoplasm: implications for systemic therapy Cancer Res. 44 1984 3643 3653
37. R.J. Hunter, M.A. Navo, P.H. Thaker, D.C. Bodurka, J.K. Wolf, and J.A. Smith Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA) Cancer Treat. Rev. 35 2009 69 78
38. M. Fung-Kee-Fung, T. Oliver, and L. Elit Optimal chemotherapy treatment in women with recurrent ovarian cancer Curr. Oncol. 14 2007 195 208
39. K.M. Field, S. Kosmider, M. Jefford, M. Michael, R. Jennens, M. Green, and P. Gibbs Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey J. Oncol. Pract. 4 2008 108 113
40. G.H. Lyman, D.C. Dale, and J. Crawford Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices J. Clin. Oncol. 21 24 2003 4524 4531
41. G.H. Lyman, D.C. Dale, D.A. Wolff, E. Culakova, M.S. Poniewierski, N.M. Kuderer, and J. Crawford Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systemic review J. Clin. Oncol. 28 17 2010 2914 2924
42. J.J. Griggs, M.E. Sorbero, and G.H. Lyman Undertreatment of obese women receiving breast cancer chemotherapy Arch. Intern. Med. 165 11 2005 1267 1273
43. C.G. Greenmann, C.H. Jagielski, and J.J. Griggs Breast cancer adjuvant chemotherapy dosing in obese women: dissemination of information from clinical trials to clinical practice Cancer 112 10 2008 2159 2165
44. M.S. Georgiadis, S.M. Steinberg, L.A. Hankins, D.C. Ihde, and B.E. Johnson Obesity and therapy-related toxicity in patients treated for small cell lung cancer 87 5 1995 361 366
45. P. Poikonen, C. Blomqvist, and H. Joensuu Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area Acta Oncol. 40 1 2001 67 71
46. G.L. Rosner Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541 J. Clin. Oncol. 14 11 1996 3000 3008
47. J. Carroll, M. Protani, E. Walpole, and J.H. Marin Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer; a systematic review Breast Cancer Res. Treat. 136 2 2012 323 330
48. M. Di Maio, C. Gridelli, C. Gallo, F. Shepherd, F.V. Piantedosi, S. Cigolari, L. Manzione, A. Illiano, S. Barbera, S.F. Robbiati, L. Frontini, E. Piazza, G.P. Ianniello, E. Veltri, F. Castiglione, F. Rosetti, V. Gebbia, L. Seymour, P. Chiodini, and F. Perrone Chemotherapy induced neutropenia and treatment efficacy in advanced non small cell lung cancer: a pooled analysis of three randomized trials Lancet Oncol. 6 9 2005 669 677
49. 2 Gynecol. Oncol. 114 1 2009 53 56
50. N.M. Protani, C.M. Nagle, and P.M. Webb Obesity and ovarian cancer survival: a systematic review and meta-analysis Cancer Prev. Res. 5 7 2012 901 910
51. J.C. Pavelka, R.S. Brown, B.Y. Karlan, I. Cass, R.S. Leuchter, L.D. Lagasse, and A.J. Li Effect of obesity on survival in epithelial ovarian cancer Cancer 107 7 2006 1520 1524
52. C. Rodriguez, E.E. Callee, D. Fakhrabadi-Shokoohi, E.J. Jacobs, and M.J. Thun Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women Cancer Epidemiol. Biomarkers Prev. 11 9 2002 822 828
53. S.V. Barrett, J. Paul, A. Hay, P.A. Vasey, S.B. Kaye, and R.M. Glasspool Does body mass index affect progression free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial Ann. Oncol. 19 2008 898 902
54. K.S. Matthews, J.M. Straughn Jr., M.K. Kemper, K.E. Hoskins, W. Wang, and R.P. Rocconi The effect of obesity on survival in patients with ovarian cancer Gynecol. Oncol. 112 2009 389 393
55. N. Katsumata, M. Yasuda, S. Isonishi, F. Takahashi, H. Michimae, E. Kimura, D. Aoki, T. Jobo, S. Kodama, F. Terauchi, T. Sugiyama, and K. Ochial Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian fallopian tube or primary peritoneal cancer (JGOG3016): a randomized, controlled open-label trial Lancet Oncol. 14 10 2013 1020 1026
56. J.D. Wright, C. Tian, D.G. Mutch, T.J. Herzog, S. Nagao, K. Fujiwara, and M.A. Powell Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group Study Gynecol. Oncol. 109 2008 353 358
57. G. Au-Yeung, P.M. Webb, A. DeFazio, S. Fereday, M. Bressel, and L. Mileshkin Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Gynecol. Oncol. 133 2014 16 22
58. T.J. Perren, A.M. Swart, J. Pfiesterer, J.A. Ledermann, E. Pajade-Lauraine, G. Kristensen, M.S. Carey, and P. Beale A phase 3 trial of bevacizumab in ovarian cancer N. Engl. J. Med. 365 26 2011 2484 2496
59. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, H. Huang, R.S. Mannel, H.D. Homesley, and J. Fowler Incorporation of bevacizumab in the primary treatment of ovarian cancer N. Engl. J. Med. 365 26 2011 2473 2483
60. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, A. Husain, and M.A. Sovak OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum sensitive recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer J. Clin. Oncol. 30 17 2012 2039 2045
61. B. Guiu, J.M. Petit, F. Bonnetain, S. Ladoire, S. Guiu, J.P. Cercueil, D. Krause, P. Hillon, C. Borg, B. Chauffert, and F. Ghiringhello Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab based treatment in metastatic colorectal cancer Gut 59 3 2010 341 347
62. L.H. Simkens, M. Koopman, L. Mol, G.J. Veldhuis, D. Ten Bokkel Huinink, E.W. Muller, V.A. Derleyn, S. Teerenstra, and C.J. Punt Influence of body mass index on outcomes in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy Eur. J. Cancer 47 17 2011 2560 2567
63. T.K. Choueiri, W. Xie, and C.K. Kollmannsberger The impact of body mass index and body surface area on treatment in metastatic renal cell carcinoma: results from a large international collaboration [abstract 4524] Presented at the 2010 American Society of Clinical Oncology Annual Meeting, Chicago Illinois, June 4-8 2010
64. K.N. Slaughter, T. Thai, S. Penaroza, D.M. Benbrook, E. Thavathiru, K. Ding, T. Nelson, D.S. McMeekin, and K.N. Moore Measurement of adiposity as clinical biomarkers for first-line bevacizumab based chemotherapy in epithelial ovarian cancer Gynecol. Oncol. 133 2014 11 15
65. V.E. von Gruenigen, C. Tian, H. Frasure, S. Waggoner, Keys, and R.R. Barakat Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma Cancer 107 12 2006 2786 2791
66. S.C. Modesitt, C. Tian, R. Kryscio, J.T. Thigpen, M.E. Randall, H.H. Callion, and G.F. Fleming Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxirubicin and cisplatin. A Gynecologic Oncology Group study Gynecol. Oncol. 105 2007 59 65